8 Tips for Successfully Developing Oligonucleotide Therapies
By Eva Gil Berglund and Nathalie H Gosselin Oligonucleotide therapeutics are a validated class of…
Certara2021 年 2 月 1 日
“Where do I start?”: Strategies for selecting the first dose for human clinical trials
This guide to dose selection for first-in-human studies explains the conceptual framework, methods, and tools…
Certara2020 年 12 月 22 日
Using a Pharmacology to Payer Framework to Support Product Development
Modeling and simulation (M&S) of complex systems has primarily advanced vertically in differing scientific domains…
Certara2018 年 3 月 16 日
Surveying the Lay of the Land for Modeling & Simulation for Global Regulatory Submissions
Analogous to how a geologist surveys the “lay of the land” to determine if oil…
Certara2018 年 2 月 16 日
Drug Asset Evaluation: Increasing “Probability of Success” of a Deal
Certara’s due diligence/asset evaluation teams are comprised of drug development and commercialization experts who advise…
Certara2017 年 8 月 24 日
Investigational Drug Gap Analysis
As the process of drug development has increased in cost and complexity, Certara has developed…
Certara2017 年 8 月 14 日
Clinical Pharmacology—The Quarterback of Drug Development
Clinical pharmacology accounts for about 50% of a drug label. Its scope ranges from facilitating…
Certara2017 年 8 月 14 日
